Active Biotech AB (ACTI.ST)
Active Biotech AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $4.25, up 2.41% on the session, giving a market capitalisation of $112.0M. Its beta of 1.34 implies it has historically moved more than the broad market.
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB is most often compared with the following Healthcare names: